Gonzalez E, Jain S, Shah P, Torimoto-Katori N, Zakharov A, Nguyn C
Drug Metab Dispos. 2021; 49(9):822-832.
PMID: 34183376
PMC: 11022912.
DOI: 10.1124/dmd.120.000320.
Carranza-Torres I, Guzman-Delgado N, Coronado-Martinez C, Banuelos-Garcia J, Viveros-Valdez E, Moran-Martinez J
Biomed Res Int. 2015; 2015:618021.
PMID: 26075250
PMC: 4449881.
DOI: 10.1155/2015/618021.
Gundert-Remy U, Dimovski A, Gajovic S
Croat Med J. 2012; 53(4):314-20.
PMID: 22911523
PMC: 3428819.
DOI: 10.3325/cmj.2012.53.314.
Roden D, Wilke R, Kroemer H, Stein C
Circulation. 2011; 123(15):1661-70.
PMID: 21502584
PMC: 3093198.
DOI: 10.1161/CIRCULATIONAHA.109.914820.
Zhou S
Clin Pharmacokinet. 2009; 48(11):689-723.
PMID: 19817501
DOI: 10.2165/11318030-000000000-00000.
Es kann die Spur von unseren Erdetagen--on pharmacologists and pharmacology.
Starke K
Naunyn Schmiedebergs Arch Pharmacol. 2009; 380(5):465-71.
PMID: 19760274
DOI: 10.1007/s00210-009-0443-7.
Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.
Ozdemir V, Suarez-Kurtz G, Stenne R, Somogyi A, Someya T, Kayaalp S
OMICS. 2009; 13(1):43-61.
PMID: 19290811
PMC: 2727354.
DOI: 10.1089/omi.2009.0011.
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y, Slanar O, Krausz K, Chen C, Slavik J, McPhail K
Drug Metab Dispos. 2006; 34(9):1563-74.
PMID: 16782768
PMC: 1553181.
DOI: 10.1124/dmd.105.008920.
Drug metabolism and pharmacogenetics: the British contribution to fields of international significance.
Caldwell J
Br J Pharmacol. 2006; 147 Suppl 1:S89-99.
PMID: 16402125
PMC: 1760745.
DOI: 10.1038/sj.bjp.0706466.
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Alvan G, Bechtel P, Iselius L, Gundert-Remy U
Eur J Clin Pharmacol. 1990; 39(6):533-7.
PMID: 2151318
DOI: 10.1007/BF00316090.
Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
Graf T, Broly F, Hoffmann F, Probst M, Meyer U, Howald H
Eur J Clin Pharmacol. 1992; 43(4):399-403.
PMID: 1451720
DOI: 10.1007/BF02220616.
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
Eichelbaum M, Spannbrucker N, Steincke B, DENGLER H
Eur J Clin Pharmacol. 1979; 16(3):183-7.
PMID: 499318
DOI: 10.1007/BF00562059.
